- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Nat Turner on Flatiron Health's Emphasis on Community Oncologists
Flatiron Health focuses on helping community oncologists because they still care for the majority of patients with cancer and make it possible for patients to get care without traveling long distances, explained Nat Turner, co-founder and CEO of Flatiron Health.
Flatiron Health focuses on helping community oncologists because they still care for the majority of patients with cancer and make it possible for patients to get care without traveling long distances, explained Nat Turner, co-founder and CEO of Flatiron Health.
Transcript (slightly modified)
Why does Flatiron Health largely focus on community oncologists?
Community oncology, for us, is critical because that’s where most of the patients are treated with cancer, so somewhere probably around 60% today—used to be 85%, but it’s probably going back to 85%—of cancer patients that are treated in community. Also, patients are generally elderly with cancer, meaning it’s harder to travel, they need to be closer to caregivers and the only true scalable solution is a close-to-home option, which community oncology can provide.
It’s not very scalable to have a hospital in every single small town in America, you really need a more distributed network and we also think it’s the best way to take care of patients, to build closer relationships with the patients, the physicians do the care teams, it’s a lot less complicated of an environment to navigate as a patient, and it’s just a lot more kind of closer touch.
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
